

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

NOVEL GAMMA-RAY STEREOTACTIC RADIOTHERAPY SYSTEM OF CNNC CHENGYING (XI'AN) MEDICAL EQUIPMENT CO., LTD. SUCCESSFULLY OBTAINED THE MEDICAL DEVICE REGISTRATION CERTIFICATE FROM NATIONAL MEDICAL PRODUCTS ADMINISTRATION (NMPA)

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (“**CIRC**” or the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, CNNC Chengying (Xi’an) Medical Equipment Co., Ltd. (“**CNNC Chengying**”), a subsidiary of CIRC, has successfully obtained the medical device registration certificate (Guo Xie Zhu Zhun 20243051214) from the National Medical Products Administration (NMPA) for its Novel Gamma-ray Stereotactic Radiotherapy System (the “**Product**”). Combined with the advanced Treatment Control System (TCS), Treatment Planning System (TPS) and Image-Guided System (IGS), the Product realises the digital and intelligent management of equipment by integrating the information generated in processes of diagnosis, imaging, planning and treatment. The Product is equipped with CBCT image guided system registration and six-dimensional bed auto-correction functions to ensure the accuracy of radiotherapy. The Product has large dose rate and powerful automation capabilities, allowing higher treatment efficiency and shorter treatment time. The professional design for the knife, which integrates head and body, enables a wider range of indications and more powerful functions.

CIRC is the only supplier of medical domestically-produced cobalt-60. The successful registration of the Product is an important achievement under CIRC's "source + equipment" collaborative model. With CIRC's domestically-produced cobalt-60 radioactive source, CNNC Chengying will adhere to the orientation to clinical application and committed to meeting clinical needs, making better radiotherapy equipment accessible to more cancer patients in China and promoting the domestic production capabilities and capacities for high-end radiotherapy equipment. The Product will contribute to the realisation of the strategic goal of "Healthy China 2030" and the improvement of national health security with its "nuclear" power.

By order of the Board
China Isotope & Radiation Corporation
Zhang Junqi
Chairman

Beijing, the PRC, 9 July 2024

As at the date of this announcement, the Board comprises Mr. Zhang Junqi and Mr. Fan Guomin as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.